AbbVie again extends Pharmacyclics offer; India high court blocks Glenmark's Januvia, Janumet knockoffs;

@FiercePharma: J&J nears $7.5M deal in Risperdal case that could have cost $1.2B. Report | Follow @FiercePharma

@EricPFierce: FDA blesses Baxter saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to go. Report | Follow @CarlyHFierce

> AbbVie ($ABBV) once again extended its tender offer for Pharmacyclics ($PCYC) stock, to Friday afternoon, as it seeks to wrap up its $21 billion purchase of the company. Report

> India's Supreme Court barred the domestic generics maker Glenmark Pharmaceuticals from selling its knockoffs of Merck & Co.'s ($MRK) diabetes drugs Januvia and Janumet, though the company can sell off existing inventory. Report

> In selling Par Pharmaceutical to Endo ($ENDP) for $8 billion, the private equity firm TPG pulled off a big gain: up to 7 times its initial equity investment in the generics maker. Report

> Retailer Meijer sued India-based Ranbaxy Laboratories over the generics maker's delays in producing copycat versions of branded meds Diovan, the Novartis ($NVS) hypertension remedy, and Valcyte, the Roche ($RHHBY) antiviral. Report

> Philadelphia-based drugmaker Lannett ($LCI) shelled out $42 million in cash to buy privately held Silarx Pharmaceuticals. Report

> In India, Fresenius Kabi Oncology challenged a Wyeth patent for Torisel (temsirolimus)--an injectable for treating renal cancer--saying that temsirolimus already was known in India before Wyeth claimed to have invented it. Report

Medical Device News

@FierceMedDev: UPDATED w/ interview: Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Advice for med tech entrepreneurs: Identify your customer and consider stakeholders' incentives carefully. Editor's corner | Follow @VarunSaxena2

@EmilyWFierce: $ILMN filed a patent infringement suit against Ariosa/$RHHBY over prenatal testing tech. Release | Follow @EmilyWFierce

> Silk Road scores FDA approval for less invasive stent system. Story

> NEA startup ClarVista gets $14.5M to gain CE mark for intraocular lens. Article

Biotech News

@FierceBiotech: ICYMI: Novo's liraglutide works in diabetes and obesity. How about NASH? More | Follow @FierceBiotech

@JohnCFierce: Got a few personal notes and saw at least 1 Twitter campaign linked to our "Influentials' list. Check out the report. Feature | Follow @JohnCFierce

> PsiOxus bags $39M from Woodford, GSK for checkpoint inhibitor combo trial. Story

> Intercept plots a big Phase III NASH trial with room for an early approval. Report

> Bluebird beats a path to early approval for its pioneering gene therapy. Article

Drug Delivery News

> 'Nanosponges' held in place with a hydrogel absorb toxins in MRSA infections. Story

> Study finds testosterone gels and patches safer than injections. More

> Endo to buy Par Pharma for $8B to bulk up in injectables. Item

> Celyad, formerly Cardio3, files for U.S. IPO worth up to $115 million. Article

> FDA approves pediatric version of Treximet to treat migraines. Report

Pharma Manufacturing News

> Pharmaniaga project in Saudi Arabia stalls but others move forward. More

> Janssen gets Rutgers' help in move to continuous manufacturing. Article

> FDA blesses Baxter saline plant in Spain to produce for U.S. More

> J&J donates $6M to Rutgers, which is helping Janssen move to continuous manufacturing. Story

> AstraZeneca says Sweden getting its new $285M biologics plant. Report

Pharma Asia News

> Wockhardt faces long haul on FDA travails, Business Today says. Story

> India's Zydus Cadila has 10 vaccines in development, set to launch next year. More

> India drug IP laws in spotlight again in local Fresenius Kabi-Pfizer case. Article

> Taiwan recalls batches of injectable sodium chloride made by Y.F. Chemical. Report

> Thailand faces pushback from private hospitals on cost claims. Item

And Finally... Dense breast tissue isn't necessarily a risk for breast cancer, a new study found. Report (sub. req.)